# US 2015/0104869 A1 · Small Activating RNA Molecules and Methods of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104869 A1
- Document ID: US20150104869A1
- Status: Published application
- Kind: A1
- Application number: 14/504,303
- Filed: 2014-10-01
- Published: 2015-04-16
- Earliest claimed: 2005-04-15
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Longcheng Li; Rajvir Dahiya
- Web page: https://patentgrep.com/patent/US20150104869A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/13: Decoys
- C12N 2310/53: partially self-complementary or closed
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions, pharmaceutical preparations, kits and methods for increasing expression of a gene product in a cell by contacting the cell with a small activating RNA (saRNA) molecule comprising a ribonucleic strand that is complementary to a non-coding nucleic acid sequence of the gene.

## Claims

### Claim at position 1

-73. (canceled)

### Claim 74

A method to increase expression of a gene comprising:
introducing a small activating RNA (saRNA) molecule into a mammalian cell in an amount sufficient to increase expression of a gene, wherein the saRNA molecule comprises at least a first ribonucleic acid strand comprising:
a 5′ region of complementarity to a promoter sequence of the gene; and
a 3′ terminal region of at least one nucleotide non-complementary to the promoter sequence,
wherein the region of complementarity comprises between about 20 to about 25 base pairs,
wherein the introducing results in an increase in expression of the gene.

### Claim 75 (depends on 74)

The method of claim 74, wherein the saRNA molecule comprises a second ribonucleic acid strand comprising a nucleotide sequence complementary to the 5′ region of complementarity of the first ribonucleic acid strand.

### Claim 76 (depends on 75)

The method of claim 75, where in the second ribonucleic acid strand comprises a 3′ terminal region of at least one nucleotide non-complementary to the first strand.

### Claim 77 (depends on 74)

The method of claim 74, wherein the saRNA molecule is introduced into the mammalian cell by expression from a nucleic acid vector.

### Claim 78 (depends on 74)

The method of claim 74, wherein the saRNA molecule comprises a thio modified internucleotide linkage.

### Claim 79 (depends on 74)

The method of claim 74, wherein the gene is a p21 gene, vascular endothelial growth factor (VEGF) gene, or E-cadherin.

### Claim 80 (depends on 74)

The method of claim 74, wherein the gene is vascular endothelial growth factor (VEGF) gene.

### Claim 81 (depends on 74)

The method of claim 74, wherein the ribonucleic acid strand comprises the sequence of SEQ ID NO:32.

### Claim 82

An isolated composition comprising,
a small activating RNA (saRNA) molecule comprising at least a first ribonucleic acid strand comprising a region of complementarity to a promoter sequence of a vascular endothelial growth factor (VEGF) gene sufficient to activate transcription of the VEGF gene, wherein the region of complementarity comprises between about 20 to about 25 base pairs.

### Claim 83 (depends on 82)

The composition of claim 82, wherein the saRNA molecule comprises a second ribonucleic acid strand comprising a nucleotide sequence complementary to the first ribonucleic acid strand.

### Claim 84 (depends on 82)

The composition of claim 82, wherein the saRNA molecule is encoded on a nucleic acid vector.

### Claim 85 (depends on 82)

The composition of claim 82, wherein the ribonucleotide strand comprises a region of non-complimentary to the non-coding nucleic acid sequence of at least one nucleotide at a 3′ terminus.

### Claim 86 (depends on 82)

The composition of claim 82, wherein the saRNA molecule comprises a thio modified internucleotide linkage.

### Claim 87 (depends on 82)

The composition of claim 82, wherein the ribonucleic acid strand comprises the sequence of SEQ ID NO:32.

### Claim 88 (depends on 82)

The composition of claim 82, wherein the composition further comprises at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a pharmaceutically acceptable excipient and a pharmaceutically acceptable adjuvant.
